How should elevated triglycerides be managed, including lifestyle modifications and pharmacologic therapy?

Management of Elevated Triglycerides

Lifestyle interventions are the absolute foundation for all patients with hypertriglyceridemia, with weight loss being the single most effective intervention—a 5-10% reduction in body weight can lower triglycerides by 20-50% 1, 2.

Risk Stratification and Treatment Goals

Your management approach depends critically on the triglyceride level and associated cardiovascular risk:

Severe Hypertriglyceridemia (≥500 mg/dL)

• Primary goal: Prevent acute pancreatitis
• Immediate aggressive triglyceride lowering is mandatory
• Once controlled, reassess for ASCVD risk 3

Moderate Hypertriglyceridemia (150-499 mg/dL)

• Primary goal: Reduce ASCVD risk
• Focus on residual cardiovascular risk reduction
• Pharmacotherapy guided by cardiovascular risk factors 1

Lifestyle Interventions (First-Line for ALL Patients)

Weight Loss (Most Effective Single Intervention)

• Target 5-10% body weight reduction → expect 20% triglyceride decrease
• Some patients achieve 50-70% reduction with weight loss alone
• Dose-response relationship exists: more weight loss = greater triglyceride reduction 1, 2

Dietary Modifications

Carbohydrate restriction is superior to low-fat diets for triglyceride lowering:

• Very low-carbohydrate diets (<10% calories from carbs) produce the greatest effect: 24 mg/dL reduction 1
• Reduce added sugars and fructose specifically—can achieve additional 10-20% reduction 2
• Eliminate trans fats and restrict saturated fats
• Increase marine-based omega-3 consumption
• Complete alcohol abstinence (especially critical when TG ≥500 mg/dL) 2

Physical Activity

• Regular aerobic exercise further optimizes triglyceride lowering 2

Combined intensive lifestyle changes can achieve ≥50% triglyceride reduction 2

Pharmacologic Management

For Severe Hypertriglyceridemia (≥500 mg/dL)

Immediate pharmacotherapy is reasonable to prevent pancreatitis, in addition to intensive lifestyle intervention 2:

Emerging first-line agents (2025-2026 data):

• ApoC-III inhibitors (volanesorsen, olezarsen, plozasiran): Achieve up to 80% triglyceride reduction and substantially reduce pancreatitis risk in familial chylomicronemia syndrome 4, 5
• These are becoming first-line for FCS as access improves 4

Established options:

• Fibrates (fenofibrate)
• High-dose omega-3 preparations (omega-3 carboxylic acid, omega-3-acid ethyl esters) 1

Critical caveat: Genetic testing should differentiate familial chylomicronemia syndrome from multifactorial causes to guide personalized therapy 4

For Moderate Hypertriglyceridemia with High ASCVD Risk

Statins are first-line to address LDL-C and overall cardiovascular risk 6

Add icosapent ethyl (IPE) 4g daily if patient meets ALL criteria 1:

• TG ≥150 mg/dL despite maximally tolerated statin therapy
• AND either:
  • Established cardiovascular disease, OR
  • Diabetes mellitus + ≥2 additional cardiovascular risk factors

This is the only triglyceride-based therapy with FDA approval for ASCVD risk reduction, showing robust reduction in MI, stroke, coronary revascularization, and unstable angina 1, 6

Important safety consideration: Icosapent ethyl carries a modest increased risk of atrial fibrillation 4

Alternative/Additional Agents

Fibrates (fenofibrate):

• Cornerstone for mixed dyslipidemia
• Particularly beneficial in diabetes for micro- and macrovascular outcomes 4
• Can be combined with statins (monitor for myopathy)

Other omega-3 preparations:

• Omega-3 carboxylic acid and omega-3-acid ethyl esters are FDA-approved only for severe hypertriglyceridemia (≥500 mg/dL), not for ASCVD risk reduction 1

Common Pitfalls to Avoid

1. Don't use nonfasting triglycerides for metabolic syndrome diagnosis or LDL-C calculation (Friedewald formula) 2
2. Rule out secondary causes first: Review medications (oral contraceptives, hormone therapy, certain antihypertensives), uncontrolled diabetes, hypothyroidism 2
3. Don't target HDL-C with drugs—despite low HDL often accompanying high triglycerides, therapies targeting HDL elevation have not shown cardiovascular benefit 7
4. For women on hormone therapy: Switch to lower estrogen oral contraceptives or transdermal preparations to blunt triglyceride increases 2
5. In patients with prior triglyceride-induced pancreatitis: Maintain especially tight control with both lifestyle and pharmacologic approaches 2

Monitoring and Reassessment

• Non-HDL cholesterol (total cholesterol minus HDL-C) is superior to LDL-C for risk assessment when triglycerides are elevated 7
• Patients with TG ≥1000 mg/dL require immediate aggressive intervention and close monitoring
• Once triglycerides are controlled from severe levels, reassess for ASCVD risk and adjust therapy accordingly 3

Emerging Therapies (2025-2026)

ANGPTL3 inhibitors (evinacumab, zodasiran) and FGF-21 agonists (pegozafermin) show early promise with substantial triglyceride reductions and potential cardiometabolic benefits, though dedicated outcome trials are needed 4, 5. These may redefine lifelong lipid management but are not yet guideline-recommended.

The treatment paradigm is rapidly evolving—referral to a lipid specialist or registered dietitian nutritionist should be strongly considered for complex cases, though referral rates remain historically low 3.